Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Aging and aging-related diseases have emerged as increasingly severe health and social problems. Therefore, it is imperative to discover novel and effective therapeutics to delay the aging process and to manage aging-related diseases. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), one of the classes of antihyperglycemic drugs, have been recommended to manage type 2 diabetes mellitus (T2DM). Moreover, GLP-1 RAs have been shown to protect against oxidative stress, cellular senescence and chronic inflammation, which are widely accepted as the major risk factors of aging. However, their significance in aging or aging-related diseases has not been elucidated. Herein, we explain the underlying mechanisms and protective roles of GLP-1 RAs in aging from a molecular, cellular and phenotypic perspective. We provide novel insights into the broad prospect of GLP-1 RAs in preventing and treating aging-related diseases. Additionally, we highlight the gaps for further studies in clinical applications of GLP-1 RAs in aging-related diseases. This review forms a basis for further studies on the relationship between aging-related diseases and GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 11×
“However, the roles of GLP- 1 RAs in AKI development among the elderly have not been fully established.”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“Furthermore, aging is often associated with changes in cell-to-cell communication, which are features of aging-related diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) [27].”
BackgroundCellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225 · cited 1×
“It is involved in various biological processes and aging-related diseases [25].”
BackgroundRubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“This is because GLP-1 RAs have shown various benefits in managing non-alcoholic fatty liver disease (NAFLD), alleviating hepatic inflammation, metabolic dysfunction, insulin resistance and lipotoxicity [171-173].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2×
“A meta-analysis evaluated seven cardiovascular studies of GLP-1 RAs, stating that GLP-1 RAs treatment can reduce broad composite kidney outcomes, including the sustained decline in eGFR, emergence of new macroalbuminuria, progression to end-stage kidney disease (ESKD), or death from renal causes [154].”
BackgroundMethodBlackburn, E. H., Epel, E. S., & Lin, J. (2015) · Science · doi:10.1126/science.aab3389 · Cited by 1,596 · cited 1×
“DNA damage signaling pathways and cellular senescence are triggered when telomeres are very short [16].”
BackgroundThe Biology of Proteostasis in Aging and Disease
Labbadia, J., & Morimoto, R. I. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033955 · Cited by 1,472 · cited 1×
“Therefore, the loss of protein homeostasis leads to aging and diseases [19-21].”
BackgroundDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Second, GLP-1 RAs influence gastrointestinal function by inhibiting gastric motility and delaying gastric emptying [63-65].”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123 · cited 1×
“NLY01, a brain-penetrant GLP-1 RA, exerts neuroprotective effects by blocking the microglialmediated transition of astrocytes into A1 neurotoxic phenotypes in PD mice [98].”
BackgroundThe sirtuin SIRT6 regulates lifespan in male mice
Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph, Z., & Cohen, H. Y. (2012) · Nature · doi:10.1038/nature10815 · Cited by 1,059 · cited 1×
“Moreover, insulin-like growth factor 1 (IGF-1), mammalian target of rapamycin (mTOR), adenosine 5’-monophosphate activated protein kinase (AMPK), and sirtuins-mediated metabolic signaling pathways are associated with the balance between nutrient anabolism and catabolism in cells, which maintain cellular homeostasis an…”
BackgroundCellular senescence drives age-dependent hepatic steatosis
Ogrodnik, M., Miwa, S., Tchkonia, T., Tiniakos, D., Wilson, C. L., Lahat, A., Day, C. P., Burt, A., Palmer, A., Anstee, Q. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15691 · Cited by 1,044
Kaushik, S., & Cuervo, A. M. (2015) · Nature Medicine · doi:10.1038/nm.4001 · Cited by 899 · cited 1×
“Therefore, the loss of protein homeostasis leads to aging and diseases [19-21].”
BackgroundAthauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“However, it is unknown whether exenatide treatments can alter the course of the underlying PD [102].”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“However, GLP-1 is less effective in preventing the progression of kidney diseases than SGLT-2 inhibitors in some cases [157].”
BackgroundMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In addition, GLP-1 RAs may inhibit bone resorption by stimulating calcitonin release from thyroid C-cells [78].”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · cited 1×
“Cardiovascular trails have shown that GLP-1 RAs can benefit CKD patients [153, 154].”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Second, GLP-1 RAs influence gastrointestinal function by inhibiting gastric motility and delaying gastric emptying [63-65].”
BackgroundExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 2×
“also indicated that liraglutide induces atrial natriuretic peptide (ANP) secretion, thereby promoting vasorelaxation [130].”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Liraglutide and lixisenatide can cross the BBB, thus enhancing neurogenesis [97].”
BackgroundSt-Onge, M.-P., & Gallagher, D. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.004 · Cited by 494
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · cited 1×
“This is because GLP-1 RAs have shown various benefits in managing non-alcoholic fatty liver disease (NAFLD), alleviating hepatic inflammation, metabolic dysfunction, insulin resistance and lipotoxicity [171-173].”
BackgroundAge-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
Chia, C. W., Egan, J. M., & Ferrucci, L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312806 · Cited by 454
The role of DNA damage and repair in aging through the prism of Koch-like criteria
Moskalev, A. A., Shaposhnikov, M. V., Plyusnina, E. N., Zhavoronkov, A., Budovsky, A., Yanai, H., & Fraifeld, V. E. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.02.001 · Cited by 387 · cited 1×
“Aging-related genomic damage is caused by both extrinsic and intrinsic factors [15].”
BackgroundAge-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases
Kubben, N., & Misteli, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.68 · Cited by 320
Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake
JafariNasabian, P., Inglis, J. E., Reilly, W., Kelly, O. J., & Ilich, J. Z. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0603 · Cited by 310
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 2×
“Moreover, considerable evidence supports that GLP-1 RAs are also associated with a modest reduction in diastolic blood pressure (DBP) in middle-aged and older patients with T2DM [127, 128].”
BackgroundCukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 1×
“GLP-1 RAs may also increase urinary sodium excretion by regulating Na/H exchanger in renal tubules [133, 134].”
BackgroundSharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 1×
“Furthermore, hepatocyte steatosis can also be inhibited by GLP-1 through inducing the response of unfolded protein [39].”
BackgroundHendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224 · cited 1×
“Second, GLP-1 RAs influence gastrointestinal function by inhibiting gastric motility and delaying gastric emptying [63-65].”
BackgroundChai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194 · cited 2×
“muscle via a NO-dependent mechanism [129]”
BackgroundGlucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · cited 1×
“Notably, GLP-1 can directly affect relaxing rat conduit arteries, independently of NO and the endothelium [131].”
BackgroundAmelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Hong, Y., Lee, J. H., Jeong, K. W., Choi, C. S., & Jun, H. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12434 · Cited by 188 · cited 1×
“Analogously, exendin-4 and dulaglutide increases muscle mass and function through the suppression of myostatin and muscle atrophic factors and enhancement of myogenic factors [169].”
BackgroundMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Chow, H.-M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., So, R. W. L., Zhang, J., & Herrup, K. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0505-1 · Cited by 171 · cited 1×
“Impaired brain insulin signaling in T2DM is closely related to AD pathogenesis [84].”
BackgroundBlood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163
GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157 · cited 1×
“Third, GLP-1 RAs directly act on adipose tissue, promote brown remodeling of white adipose tissue and fat mobilization, accelerating fat burning and thus achieving sustained weight loss [66].”
BackgroundMann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157 · cited 3×
“Aging and Disease • Volume 13, Number 2, April 2022 476 GLP-1 RAs systematic review and meta-analysis 93502 (≥65) / GLP-1 RAs reduced MACE [55] GLP-1 RAs plus SGLT2i observational, prospective, multicenter study 113 (>65) / Combination therapy was tolerated well and reduced A1C level, body weight and SBP [56] Obesity…”
MethodInfluentialGaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146 · cited 1×
“GLP-1 RAs have a lower risk of diabetic ketoacidosis, lower-limb amputations, and genital infections and similar major adverse cardiovascular events (MACE) risk among older adults compared with sodium-dependent glucose transporters 2 (SGLT2) inhibitors [54, 55].”
BackgroundVinué, Á., Navarro, J., Herrero-Cervera, A., García-Cubas, M., Andrés-Blasco, I., Martínez-Hervás, S., Real, J. T., Ascaso, J. F., & González-Navarro, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4330-3 · Cited by 137
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135 · cited 1×
“Liraglutide can significantly reduce LDL-C, TG, and CIMT levels in T2DM and metabolic syndrome [122].”
BackgroundChen, J., Xie, J.-J., Shi, K.-S., Gu, Y.-T., Wu, C.-C., Xuan, J., Ren, Y., Chen, L., Wu, Y.-S., Zhang, X.-L., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0217-y · Cited by 130 · cited 2×
“At the cellular level, the GLP-1 receptor mediates the protective effects of liraglutide in chondrocytes, preventing endoplasmic reticulum stress and apoptosis [166].”
BackgroundPerna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 4×
“Another prospective study with nine subjects demonstrated that a 24-week liraglutide treatment could effectively reduce fat mass in overweight and obese elderly with T2DM [71].”
BackgroundInfluentialEffects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney
Jang, I.-A., Kim, E. N., Lim, J. H., Kim, M. Y., Ban, T. H., Yoon, H. E., Park, C. W., Chang, Y. S., & Choi, B. S. (2018) · Nutrients · doi:10.3390/nu10111741 · Cited by 110 · cited 1×
“Kidney aging in diabetic individuals involves cellular senescence, AGEs accumulation, reninangiotensin-aldosterone system (RAAS) dysfunction, inflammation, and oxidative stress [139, 141-143].”
BackgroundAging-induced biological changes and cardiovascular diseases.
Fajemiroye, J. O., Cunha, L. C. D., Saavedra-Rodríguez, R., Rodrigues, K. L., Naves, L. M., Mourão, A. A., Silva, E. F. D., Williams, N. E. E., Martins, J. L. R., Sousa, R. B., et al. (2018) · BioMed Research International · doi:10.1155/2018/7156435 · Cited by 109 · cited 1×
“Aging alters the vascular structure and function, such as intimal thickening, inflammation, and lipid deposition, thus accelerating the progression of atherosclerotic diseases [112].”
BackgroundJojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Reduction in podocyte SIRT1 accelerates kidney injury in aging mice
Chuang, P. Y., Cai, W., Li, X., Fang, L., Xu, J., Yacoub, R., He, J. C., & Lee, K. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00255.2017 · Cited by 98 · cited 1×
“Moreover, downregulation of anti-aging gene klotho and Sirt1 and the impairment of lysosome-dependent autophagy promote DKD development [139, 144-146].”
BackgroundQue, Q., Guo, X., Zhan, L., Chen, S., Zhang, Z., Ni, X., Ye, B., & Wan, S. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0218-y · Cited by 90
Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
Gurjar, A. A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., China, S. P., Kumar, H., Trivedi, A. K., Guha, R., Chattopadhyay, N., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154044 · Cited by 79 · cited 2×
“Additionally, the disrupted structure of myofibrillar was restored by liraglutide in some muscle atrophy models [168].”
BackgroundZhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists
Dubois-Laforgue, D., Boutboul, D., Lévy, D. J., Joly, D., & Timsit, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.014 · Cited by 30 · cited 1×
“A few cases of GLP-1 RAs-induced AKI have been reported in middleaged and elderly patients [160-162].”
Backgroundc-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines
Pacheco-Pantoja, E. L., Dillon, J. P., Wilson, P. J. M., Fraser, W. D., & Gallagher, J. A. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9526-3 · Cited by 21
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16 · cited 1×
“Furthermore, oral semaglutide was recently approved for treating T2DM in elderly patients with or without comorbidities [53].”
Background
Cited by
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Liu, H., Huang, Z., Deng, B., Chang, Z., Yang, X., Guo, X., Yuan, F., Yang, Q., Wang, L., Zou, H., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0514 · Cited by 20
Metadata
- Authors
- Peng, W., Zhou, R., Sun, Z.-F., Long, J.-W., & Gong, Y.-Q.
- Venue
- Aging and disease
- Publisher
- Aging and Disease
- Published
- 2022
- Volume
- 13
- Issue
- 2
- Pages
- 468
- ISSN
- 2152-5250 (ISSN-L)
- OpenAlex
- W4226038449
- Cited by
- 71
- References
- 70
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.